FDA approves Pierre Fabre/Array Biotech melanoma combo
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
Read More
Tag: Array
Pierre Fabre, Array showcase potential of triple therapy for CRC
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
Read More
Merck links with Array, Pierre Fabre to test cancer combo
Germany’s Merck has linked with Array BioPharma and Pierre Fabre to initiate a lage-stage trial assessing the efficacy of a new combination therapy in BRAF-mutant metastatic colorectal cancer.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
